Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) TA1006 12 September 2024 12 September 2024 Evinacumab for treating homozygous familial hypercholesterolaemia ...

The appraisal committee has prepared final draft guidance (FDG) on Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer and submitted it to ...

NICE has recommended belzutifan for some adults with Von Hippel-Lindau disease, in final draft guidance, which could benefit ...

You can now review and comment on this draft guideline which will partially update Advanced breast cancer: diagnosis and treatment (CG81) and Early and locally advanced breast cancer: diagnosis and ...

There is a simple discount patient access scheme for faricimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'inputs and eligible population' and 'unit costs' worksheets in the template to reflect ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

The company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time.

NICE is unable to make a recommendation about the use in the NHS of empagliflozin for treating type 2 diabetes in people aged 10 to 17 years. This is because Boehringer Ingelheim has confirmed that it ...

Tools to help you put the guidance into practice.

NICE is unable to make a recommendation about the use in the NHS of empagliflozin (Jardiance) for treating type 2 diabetes in people aged 10 to 17 years. This is because Boehringer Ingelheim did not ...